Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Knee Osteoarthritis, Osteo Arthritis Knee
Interventions: Microfragmented Adipose Tissue derived using the Lipogems® System, Saline Injection; Device · Drug
Lead sponsor: Lipogems International spa; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 16
States / cities: Phoenix, Arizona • Encinitas, California • La Mesa, California + 13 more

Conditions: Cholangiocarcinoma, Multiple Myeloma, Colon Cancer, Rectal Cancer
Interventions: Return of Genetic Results: Biomarker information from cancer cells, Return of Genetic Results: Inherited mutations related to cancer, Return of Genetic Results: Inherited mutations related to other medical issues; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Pain
Interventions: Yoga, Music Therapy; Behavioral
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Active Polyarticular Juvenile Idiopathic Arthritis
Interventions: Abatacept; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 12
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 9 more

Conditions: Rheumatoid Arthritis
Interventions: Belatacept, Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 20
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 17 more

Conditions: Healthy Volunteers
Interventions: ozanimod; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Austin, Texas • San Antonio, Texas

Conditions: Dementia, Postoperative Delirium (POD), Postoperative Neurocognitive Disorder, Major Adverse Cardiac and Cerebrovascular Events, Perioperative Complications, Postoperative Cognitive Decline
Interventions: Personalized CPC Prehabilitation, Cognitive Training, Meditation, Daily Exercise, Enhanced Social Support, Proactive Bundle Interventions, Pre-operative Standard of Care, Intra-operative Standard of Care; Other · Behavioral · Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Pittsburgh, Pennsylvania

Conditions: Stroke, Stroke, Acute, Stroke Hemorrhagic, Hemiparesis, Hemiplegia, Cerebrovascular Accident
Interventions: ReWalk ReStore device; Device
Lead sponsor: ReWalk Robotics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 5
States / cities: Chicago, Illinois • Boston, Massachusetts • West Orange, New Jersey + 2 more

Conditions: Medication Adherence
Interventions: Survey; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Davis, California • Indianapolis, Indiana • Minneapolis, Minnesota + 5 more

Conditions: Cognitive Impairment, Vascular Diseases, Alzheimer Disease, Atherosclerosis
Interventions: 11C-PIB; Drug
Lead sponsor: José A. Luchsinger; Other
Eligibility: 60 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: PF-04965842 200 mg, PF-04965842 100 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Encinitas, California • Los Angeles, California • Largo, Florida + 5 more

Conditions: Non-small Cell Lung Cancer
Interventions: sunvozertinib, Pemetrexed+carboplatin; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 15
States / cities: Glendale, California • Vallejo, California • Aurora, Colorado + 10 more

Conditions: Pancreatic Neoplasms
Interventions: RenovoCath™ R120 Catheter; Device
Lead sponsor: RenovoRx; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 5
States / cities: San Jose, California • Port Charlotte, Florida • Tampa, Florida + 2 more

Conditions: Paroxysmal Supraventricular Tachycardia
Interventions: Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System; Drug · Device
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 22
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Alamitos, California + 18 more

Conditions: Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease, Stroke, Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 5,290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Aliso Viejo, California

Conditions: Small Cell Lung Carcinoma
Interventions: JDQ443; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Conditions: Advanced Solid Tumors
Interventions: intravenous (IV) infusion; Drug
Lead sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 11
States / cities: Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 8 more

Conditions: NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease
Interventions: CRV431 75mg, Placebo (1 softgel), CRV431 225mg, Placebo (3 softgels); Drug
Lead sponsor: Hepion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Orange, California • Poway, California • Miami, Florida + 5 more

Conditions: Lateral Epicondylitis
Interventions: rhPDGF-BB Injection, Placebo; Drug
Lead sponsor: BioMimetic Therapeutics; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 3 more

Conditions: Alport Syndrome, Focal Segmental Glomerulosclerosis
Interventions: R3R01; Drug
Lead sponsor: River 3 Renal Corp.; Industry
Eligibility: 12 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 14
States / cities: Los Angeles, California • Boca Raton, Florida • Miami, Florida + 11 more

Conditions: HCC
Interventions: GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012; Biological · Device
Lead sponsor: Geneos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more

Conditions: Spinal Cord Injury, Paralysis, Tetraplegia, Paraplegia
Interventions: IST-16 (16-Channel implanted stimulator-telemeter; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acne Vulgaris
Interventions: Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Atopic Disease (Including Allergic Conjunctivitis)
Interventions: Drug: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Search by objective public record fields.

Microfragmented Adipose Tissue Compared to Saline Injection for the Treatment of Knee Osteoarthritis

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

POP SINGER Randomized Clinical Trial

Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis

Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites

Prediction and Prevention of Postoperative Mortality and Morbidity

Safety Evaluation of the ReWalk ReStore Device in Subjects With Mobility Impairments Due to Stroke

Perspectives on Prophylactic Antibiotic Use in Dermatologic Surgery

11C-PIB PET Study in MESA at Columbia University

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

PRISM Registry: Pseudobulbar Affect Registry Series

A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

A Neuroprosthesis for Prolonged Standing After SCI Using Multi-Contact Peripheral Nerve Electrodes

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

A Multi-Center Study Evaluating the Safety of AC-170 0.24%